Andrew D. Simmons, Ph.D. is currently an Associate Director of Translational Medicine at Clovis Oncology with over 20 years of cellular and molecular biology experience working in academic, biotech, and pharmaceutical settings. He previously worked at Takeda California, and led efforts to develop novel and potent small molecule, antibody, and ADC oncology therapeutics. Prior to that, Dr. Simmons worked at two different companies focused on use of viral vectors and fungi to develop novel antibody expression systems. For more than 8 years he was a scientist at Cell Genesys, and aided in the preclinical development of lentiviral gene therapy vectors and GVAX, an active cell based cancer immunotherapy. During his career Dr. Simmons has contributed to multiple agents that either have been or are currently in clinical development, and is an author on numerous publications and patents. He received a BS in cell and molecular biology from Texas Tech University, and a PhD in biochemistry from the University of Texas Southwestern Medical Center.
Andrew D. Simmons, Ph.D.